{"id":2155,"date":"2019-10-02T12:21:52","date_gmt":"2019-10-02T10:21:52","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2155"},"modified":"2025-06-18T11:07:58","modified_gmt":"2025-06-18T09:07:58","slug":"neurologic-diseases-and-neurogenetics-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/neuroscience-area\/neuroscience-program\/neurologic-diseases-and-neurogenetics-2\/","title":{"rendered":"Neurologic Diseases and Neurogenetics"},"content":{"rendered":"\n

\n\t\tNeurologic diseases and neurogenetics\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t
This group undertakes the challenges of developing advanced treatments for patients with movement disorders, refractory epilepsy, neuropathies, myasthenia, myopathies, etc., in addition to the work carried out with the Multiple Sclerosis Unit and the Multidisciplinary Unit for Patients with Amyotrophic Lateral Sclerosis (thanks to the collaboration with the Miquel Valls Foundation).he group works in the development of new diagnostic and prognostic biomarkers and cl\u00ednical, epidemiological studies in neurologial diseases.<\/p>\n

619<\/h2>\n

Publications<\/h2>\n\t\t\t\t $\"pyramidal_hippocampal_neuron_40x\"$ \n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\t Expand<\/i><\/a>\n\t\t\t\t\tBiomarkers in neurological disease: ALS, MS, Alzheimer’s Disease…
\nNew therapeutic strategies in Neurological Diseases
\nEpidemiology of Neurological Disease: ALS, neurovascular disorders, dementia, Multiple Sclerosis
\nLexical access disorders in speech production
\nProthrombotic mechanisms in patients with Stroke
\nNeurophysiological markers in postanoxic patients
\nNeuronal networks and Epilepsy
\nPersonalized and Precision Medicine in neurological disease
\nPrognostic studies in movement disorders, multiple sclerosis, ALS, neurovascular, dementia…\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\t Expand<\/i><\/a>\n\t\t\t\t\t\n
Sarraj,A;Abraham,MG;Hassan,AE;Blackburn,S;Kasner,SE;Ortega Gutierrez,S;Hussain,MS et al, Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial., Lancet, 2024;403(10428):731-740, doi:10.1016\/S0140-6736(24)00050-3<\/li>\n
Andr\u00e9s Benito,P;V\u00e1zquez Costa,JF;Garz\u00f3n,NCN;Colomina,MJ;Marco,C;Gonz\u00e1lez,L;Terrafeta,C et al, Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen, Int J Mol Sci, 2024;25(7):doi:10.3390\/ijms25073810<\/li>\n
Arroyo Pereiro P, Mu\u00f1oz-Vendrell A, Le\u00f3n Moreno I, Bau L, Matas E, Romero-Pinel L, Mart\u00ednez Y\u00e9lamos A, Mart\u00ednez Y\u00e9lamos S, Andr\u00e9s-Benito P. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort. J Neurol. 2024 Apr;271(4):1599-1609. doi: 10.1007\/s00415-023-12135-w<\/li>\n
Naval Baudin,P;Pons Escoda,A;Castillo Pinar,A;Mart\u00ednez Zalacain,I;Arroyo Pereiro,P;Flores Casaperalta,S;Garay Buitron,F et al, The T1-dark-rim: A novel imaging sign for detecting smoldering inflammation in multiple sclerosis, Eur J Radiol, 2024;173111358-111358, doi:10.1016\/j.ejrad.2024.111358<\/li>\n
Roca Pereira,S;Dom\u00ednguez,R;Le\u00f3n,IM;Colomina,MJ;Y\u00e9lamos,AM;Y\u00e9lamos,SM;Povedano,M et al, Increased CXCL12, a potential CSF biomarker for differential diagnosis of amyotrophic lateral sclerosis, Brain Commun, 2024;6(4):doi:10.1093\/braincomms\/fcae271<\/li>\n<\/ul>\n\t\t\t\t\t Selected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\t Expand<\/i><\/a>\n\t\t\t\t\t\n
CPP2022-009778. NexTOLL: A Phase IIb Clinical trial to the evaluate neuroprotective effect of ApTOLL in stroke patients. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 485.715,5\u20ac. 2023-2026. PI: Cardona Portela, Pere.<\/li>\n
HNA. Caracterizaci\u00f3n de las v\u00edas moleculares subyacentes en el espectro patol\u00f3gico ELA-DFT en base a la expresi\u00f3n fenot\u00edpica: nuevos biomarcadores. FUNDACI\u00d3N HNA. Budget: 87.780\u20ac. 2024-2026. PI: POVEDANO PANADES, MONICA.<\/li>\n
2022-135-1. Red de ensayo secuencial de grupo, adaptativa y de multi-rama para evaluar la eficacia de f\u00e1rmacos en pacientes con Esclerosis Lateral Amiotr\u00f3fica (ELA). STICHTING TRICALS FOUNDATION. Budget: 54.427,5\u20ac. 2022- . PI: MONICA POVEDANO PANADES.<\/li>\n
2023-649-1. ESTUDIO DE FASE 3, DOBLE CIEGO, ALEATORIZADO, COMPARANDO LA EFICACIA Y SEGURIDAD DE FREXALIMAB (SAR441344) CON PLACEBO EN PARTICIPANTES ADULTOS CON ESCLEROSIS M\u00daLTIPLE SECUNDARIA PROGRESIVA SIN RECA\u00cdDAS. Sanofi-Aventis, S.A.. Budget: 341.480\u20ac. 2024- . PI: Sergio Mart\u00ednez Y\u00e9lamos.<\/li>\n
2023-443-1. THE PIVOTAL STUDY OF RAPIDPULSETM ASPIRATION SYSTEM AS FRONTLINE APPROACH FOR PATIENTS WITH ACUTE ISCHEMIC STROKE DUE TO LARGE VESSEL OCCLUSIONS (“RAPIDPULSE PIVOTAL STUDY”). RapidPulse, Inc. Budget: 266.900\u20ac. 2024- . PI: Pere Cardona Portela.<\/li>\n<\/ul>\n\t\t\t\t\t Technology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\t Expand<\/i><\/a>\n\t\t\t\t\tLicense: TECNOLOG\u00cdA PARA LA TELEASISTENCIA Y GEOLOCALIZACI\u00d3N INAL\u00c1MBRICA DE PACIENTES
\nPI: Dr. Pere Cardona\nPatent: PAT078-IN VITRO METHOD AND KIT FOR THE PROGNOSIS OF AMYOTROPHIC LATERAL SCLEROSIS
\nIP: Monica Povedano
\nEP20382463\n\t\t\t\t\tMore information<\/a>\n\t\t\t\t\t\t\t\t\t\t\t Expand<\/i><\/a>\n\t\t\t\t\t
PROJECTS<\/strong><\/p>\n
\n
Title:<\/strong>\u00a0Activation of the resolution programs of inflammation as a novel therapeuthic approach for the treatment of amyotrophic lateral sclerosis<\/li>\n
PI:\u00a0<\/strong>Povedano Padanes, M\u00f2nica<\/li>\n
Coordinator:<\/strong>\u00a0Universitat Aut\u00f2noma de Barcelona- UAB (Project Leader: Dr. Rub\u00e8n L\u00f3pez Vales)<\/li>\n
Call reference:\u00a0<\/strong>Health Research 2017 Call for proposals, expediente: HR17-00777<\/li>\n
Funder:<\/strong>\u00a0Fundaci\u00f3 “la Caixa”<\/li>\n<\/ul>\n\t\t\t\t $\"Antonio-Martinez-Yelamos22\"$ \n
\n\t\tMartinez Yelamos, Antonio\n\t<\/h4>\n
\n\t\t \n\t\tamyelamos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadores principales\n\t<\/h2>\n\t\t\t\t $\"Antonio-Martinez-Yelamos22\"$ \n
\n\t\tMartinez Yelamos, Antonio\n\t<\/h4>\n
\n\t\t \n\t\tamyelamos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"avatar\"$ \n
\n\t\tPrat Rojo, Joan\n\t<\/h4>\n
\n\t\t \n\t\tjprat@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Julia-Miro-Llado\"$ \n
\n\t\tMir\u00f3 Llad\u00f3, J\u00falia\n\t<\/h4>\n
\n\t\t \n\t\tjmiro@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Mariano-Huerta-Villanueva\"$ \n
\n\t\tHuerta Villanueva, Mariano\n\t<\/h4>\n
\n\t\t \n\t\tmhuerta@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Jordi-Gascon-Bayarri\"$ \n
\n\t\tGasc\u00f3n Bayarri, Jordi\n\t<\/h4>\n
\n\t\t \n\t\trrene@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Monica-Povedano-Panades\"$ \n
\n\t\tPovedano Panades, M\u00f2nica\n\t<\/h4>\n
\n\t\t \n\t\tmpovedano@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Sergio-Martinez-Yelamos\"$ \n
\n\t\tMartinez Yelamos, Sergio\n\t<\/h4>\n
\n\t\t \n\t\tsmartinezy@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Helena-Bejr-Kasem-Marco\"$ \n
\n\t\tBejr-Kasem Marco, Helena\n\t<\/h4>\n\t\t\t\t $\"avatar\"$ \n
\n\t\tCalopa Garriga, Matilde\n\t<\/h4>\n
\n\t\t \n\t\tmcalopa@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Lucia-Aja-Rodriguez\"$ \n
\n\t\tAja Rodriguez, Lucia\n\t<\/h4>\n
\n\t\t \n\t\tlaja@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Serge-Jauma-Classen\"$ \n
\n\t\tJauma Classen, Serge\n\t<\/h4>\n
\n\t\t \n\t\tsjauma@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Pere-Cardona-Portela\"$ \n
\n\t\tCardona Portela, Pere\n\t<\/h4>\n
\n\t\t \n\t\tpcardona@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Merce-Falip-Centellas\"$ \n
\n\t\tFalip Centellas, Mercedes\n\t<\/h4>\n
\n\t\t \n\t\tmfalip@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t $\"Cristina-Sanchez-Casta\u00f1eda\"$ \n
\n\t\tSanchez Casta\u00f1eda, Cristina\n\t<\/h4>\n
\n\t\t \n\t\tcsanchez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tRELATED LINKS\n\t<\/h4>\n
\n\t\t \n\t\t@SMYelamos\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t \n\t\t@ToniMartYelamos\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t \t\t\t\tGroup Leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t \t\t\t\tPrincipal Investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t \t\t\t\tClinical Investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t \t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t \t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t \t\t\t\tManagement support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup Leaders\n\t\t\t\t\t\t\t\t\t\t\t
\n
Martinez Yelamos, Antonio<\/li>\n<\/ul>\n\t\t\t\t\t\tPrincipal Investigators\n\t\t\t\t\t\t\t\t\t\t\t
\n
Bejr-Kasem Marco, Helena<\/li>\n
Calopa Garriga, Matilde<\/li>\n
Cardona Portela, Pere<\/li>\n
Falip Centellas, Merc\u00e8<\/li>\n
Gascon Bayarri, Jordi<\/li>\n
Huerta Villanueva, Mariano<\/li>\n
Jauma Classen, Serge<\/li>\n
Mart\u00ednez Y\u00e9lamos, Sergio<\/li>\n
Mir\u00f3 Llad\u00f3, Julia<\/li>\n
Povedano Panades, Monica<\/li>\n
Prat Rojo, Joan<\/li>\n
Sanchez Casta\u00f1eda, Cristina<\/li>\n<\/ul>\n\t\t\t\t\t\tClinical Investigators\n\t\t\t\t\t\t\t\t\t\t\t
\n
Arroyo Pereiro, Pablo<\/li>\n
Bau Vila, Laura<\/li>\n
Campdelacreu Fumado, Jaume<\/li>\n
Dom\u00e8nech Santasusana, Pere<\/li>\n
Dom\u00ednguez Rubio, Ra\u00fal<\/li>\n
Dot Bach, Dolors<\/li>\n
Fern\u00e1ndez Conejero, Isabel<\/li>\n
Gonz\u00e1lez Mera, Laura<\/li>\n
Lara Rodr\u00edguez, Blanca<\/li>\n
Leon Moreno, Maria Isabel<\/li>\n
Matas Mart\u00edn, Elisabet<\/li>\n
Mu\u00f1oz Vendrell, Albert<\/li>\n
Nedkova Hristova, Velina<\/li>\n
Paipa Merchan, Andres Julian<\/li>\n
Romero Gangonells, Elisabet<\/li>\n
Romero Pinel, Lucia Maria<\/li>\n
Veciana Veciana De Las Heras, Misericordia<\/li>\n<\/ul>\n\t\t\t\t\t\tPredoctoral researchers\n\t\t\t\t\t\t\t\t\t\t\t
\n
Gomez Llopico, Roser<\/li>\n
Lopez Sampere, Yaiza<\/li>\n
Mengod Soler, Pol<\/li>\n
Mu\u00f1oz Qui\u00f1ones, Silvia<\/li>\n
Riera Nu\u00f1ez, Estefania<\/li>\n
Roca Pereira, Sergio<\/li>\n<\/ul>\n\t\t\t\t\t\tScientific support\n\t\t\t\t\t\t\t\t\t\t\t
\n
\u00c1lvarez Fornieles, Sheila<\/li>\n
Conde Gonzalvo, Eloy<\/li>\n
Esteban Barrigon, Isabel<\/li>\n
Vinyals Rioseco, Antonia<\/li>\n
Zamorano Garcia, Gisela<\/li>\n<\/ul>\n\t\t\t\t\t\tManagement support\n\t\t\t\t\t\t\t\t\t\t\t
\n
Borges Ballester, Guillem<\/li>\n
Moreno Morej\u00f3n, Jos\u00e9 Luis<\/li>\n
Pobla M\u00fcller, Susana<\/li>\n
Terrafeta Pastor, Cristina<\/li>\n<\/ul>\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t <\/a>\n\t\t\t IDIBELL brings neuroscience closer to the public within the framework of the Brain Week in L’Hospitalet<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t14\/03\/2025\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t The Niemann-Pick Foundation donates nearly 105,000 euros to continue with the clinical trial of a drug to stop the disease-related cognitive deterioration<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t09\/11\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t hna Foundation awards a project led by Dr. Povedano on biomarkers for the detection of ALS<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t31\/05\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t The Pinnae Foundation organizes a charity dinner to support ALS research<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t24\/05\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t A study published in ‘NEJM’ expands the range of stroke patients who can benefit from thrombectomy<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t09\/05\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t Genetic testing improves diagnosis of the causes of epilepsy<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t12\/02\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t Swim for ELA, IDIBELL and Bellvitge Hospital, together against ALS<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t08\/02\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t The Ministry of Science and Innovation awards \u20ac4 million for the Phase 2b clinical trial with a new drug for ischemic stroke<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/01\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t Imaging biomarker may help to better understand and treat progressive multiple sclerosis<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t23\/08\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t <\/a>\n\t\t\t A new neuroprotective drug shows good preliminary results for ischemic stroke<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t02\/08\/2023\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"
Neurologic diseases and neurogenetics Summary This group undertakes the challenges of developing advanced treatments for patients with movement disorders, refractory epilepsy, neuropathies, myasthenia, myopathies, etc., in addition to the work carried out with the Multiple Sclerosis Unit and the Multidisciplinary Unit for Patients with Amyotrophic Lateral Sclerosis (thanks to the collaboration with the Miquel Valls […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":503,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-2155","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2025-07-12 07:48:00","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=2155"}],"version-history":[{"count":6,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2155\/revisions"}],"predecessor-version":[{"id":25964,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2155\/revisions\/25964"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/503"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=2155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}